Spyre Therapeutics, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
SYRE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10 Apr 2026

Quick Takeaways

  • SYRE - Spyre Therapeutics, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2025.
  • Headline metric: Return On Equity -25%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-58%</span>.
  • Most recent SEC facts end date: 12 Feb 2026.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2026-02-12) highlights Return On Equity -25.2%, Return On Assets -22.4%, and Current Ratio 13.25x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

38.3/100

Weak Confidence medium

Return On Equity

-25%

Metric score 0.0/100

Return On Assets

-22%

Metric score 0.0/100

Financial Health

Current Ratio
13.25x
Debt to Equity
0.13x

Strengths

Debt-to-equity and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Return On Equity

-25%

YoY: -58%

Industry median: -43% (n=675)

View history

Return On Assets

-22%

YoY: -49%

Industry median: -47% (n=673)

View history

Current Ratio

13.25x

YoY: +18%

Industry median: 3.39x (n=667)

View history

Debt-to-equity

0.13x

YoY: -44%

Industry median: 0.26x (n=530)

View history

NetIncomeLoss YoY

25%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -25% -58%
Return On Assets -22% -49%

Financial Health

Metric Latest value YoY change
Current Ratio 13.25x +18%
Debt-to-equity 0.13x -44%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY 25%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 78,540,164
Common Stock, Shares, Outstanding 78,189,811 +30%
Common Stock, Value, Issued $15,000 +15%

Additional Metrics

Metric Latest value YoY change
General and Administrative Expense $47,909,000 +4.7%
Operating Income (Loss) $209,562,000 -0.48%
Nonoperating Income (Expense) $54,344,000 +8972%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $155,218,000 +25%
Income Tax Expense (Benefit) $15,000 -129%
Cash and Cash Equivalents, at Carrying Value $85,721,000 -4.1%
Cash, Cash Equivalents, and Short-term Investments $756,500,000 +25%
Assets, Current $777,781,000 +28%
Other Assets, Noncurrent $0 -100%
Assets $777,781,000 +28%
Liabilities, Current $58,685,000 +8.6%
Liabilities $62,545,000 -31%
Accumulated Other Comprehensive Income (Loss), Net of Tax $869,000 +383%
Retained Earnings (Accumulated Deficit) $1,127,635,000 -16%
Stockholders' Equity Attributable to Parent $715,236,000 +38%
Liabilities and Equity $777,781,000 +28%
Common Stock, Shares Authorized 400,000,000 0%
Common Stock, Shares, Issued 78,189,811 +30%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85,721,000 -4.1%
Deferred Tax Assets, Valuation Allowance $201,345,000 +24%
Deferred Tax Assets, Gross $201,528,000 +24%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $154,514,000 +26%
Deferred Tax Assets, Operating Loss Carryforwards $118,511,000 +36%
Preferred Stock, Shares Authorized 10,000,000 0%
Unrecognized Tax Benefits $0
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY